Last €4.14 EUR
Change Today +0.04 / 0.97%
Volume 0.0
6TY1 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:17 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (6TY1) Snapshot

Open
€4.14
Previous Close
€4.10
Day High
€4.14
Day Low
€4.14
52 Week High
01/16/14 - €14.16
52 Week Low
07/21/14 - €4.10
Market Cap
64.4M
Average Volume 10 Days
85.0
EPS TTM
--
Shares Outstanding
15.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OCERA THERAPEUTICS INC (6TY1)

Related News

No related news articles were found.

ocera therapeutics inc (6TY1) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (6TY1) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company was founded in 2004 and is headquartered in Palo Alto, California.

14 Employees
Last Reported Date: 03/18/14
Founded in 2004

ocera therapeutics inc (6TY1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $198.8K
Chief Medical and Development Officer and Dir...
Total Annual Compensation: $398.3K
Compensation as of Fiscal Year 2013.

ocera therapeutics inc (6TY1) Key Developments

Ocera Therapeutics, Inc. Appoints Sharon Tetlow as Acting Chief Financial Officer and Treasurer

On June 11, 2014, the board of directors of Ocera Therapeutics, Inc. appointed Sharon Tetlow as Acting Chief Financial Officer and Treasurer of the company. The board also selected Ms. Tetlow to perform the duties of the company's principal financial officer and principal accounting officer. On June 2, 2014, the company entered into a consulting agreement with Danforth Advisors, LLC, pursuant to which Ms. Tetlow will provide the company with certain strategic and financial advice and support services during the one-year period beginning on June 2, 2014. The company will pay Danforth a consulting fee of $325 per hour for Ms. Tetlow's services. The consulting agreement may be terminated either by the company or by Danforth without cause upon 90 days' prior written notice. Ms. Tetlow, has worked as a Managing Director at Danforth, since April 2013. Prior to working at Danforth, Ms. Tetlow served as the Chief Financial Officer of Pathwork Diagnostics, from 2011 until March 2013.

Ocera Therapeutics, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM

Ocera Therapeutics, Inc. Presents at JMP Securities Healthcare Conference, Jun-25-2014 12:30 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States.

Ocera Therapeutics, Inc. Announces Resignation of Jeryl L. Hilleman as Chief Financial Officer and Secretary of the Company, Effective June 3, 2014

On May 16, 2014, Jeryl L. Hilleman resigned as the Chief Financial Officer and Secretary of Ocera Therapeutics, Inc., effective as of June 3, 2014, to pursue a new career opportunity. Ms. Hilleman's resignation was not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
6TY1:GR €4.14 EUR +0.04

6TY1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 6TY1.
View Industry Companies
 

Industry Analysis

6TY1

Industry Average

Valuation 6TY1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 671.4x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 527.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit www.ocerainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.